Literature DB >> 2661486

Cancer of the esophagus: the Wayne State University experience.

L Leichman1.   

Abstract

The rationale for the preoperative therapy for cancer of the esophagus is described. The first trial with infusion FUra mitomycin-c and radiation performed at Wayne State University (WSU) is described. The dramatic responses were duplicated when cisplatin was substituted for mitomycin. Moreover, survival was improved over the mitomycin-c trial. These neoadjuvant trials led to a third WSU clinical trial in which the neoadjuvant therapy became the definitive therapy.

Entities:  

Mesh:

Year:  1989        PMID: 2661486     DOI: 10.1007/bf00178195

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  33 in total

1.  Combined therapy for cancer of the anal canal: a follow-up report.

Authors:  T R Buroker; N Nigro; G Bradley; L Pelok; C Chomchai; B Considine; V K Vaitkevicius
Journal:  Dis Colon Rectum       Date:  1977 Nov-Dec       Impact factor: 4.585

2.  Combined modality therapy for esophageal squamous cell carcinoma.

Authors:  R Franklin; Z Steiger; G Vaishampayan; I Asfaw; J Rosenberg; J Loh; J Hoschner; P Miller
Journal:  Cancer       Date:  1983-03-15       Impact factor: 6.860

3.  Preoperative chemotherapy, surgical resection, and selective postoperative therapy for squamous cell carcinoma of the esophagus.

Authors:  A D Hilgenberg; R W Carey; E W Wilkins; N C Choi; D J Mathisen; H C Grillo
Journal:  Ann Thorac Surg       Date:  1988-04       Impact factor: 4.330

4.  Carcinoma of the esophagus.

Authors:  R A Cukingnan; J S Carey
Journal:  Ann Thorac Surg       Date:  1978-09       Impact factor: 4.330

5.  Computed tomography for staging esophageal and gastroesophageal cancer: reevaluation.

Authors:  W M Thompson; R A Halvorsen; W L Foster; M E Williford; R W Postlethwait; M Korobkin
Journal:  AJR Am J Roentgenol       Date:  1983-11       Impact factor: 3.959

Review 6.  Treatment of cultured human colon carcinoma cells with fluorinated pyrimidines.

Authors:  B Drewinko; L Y Yang; D H Ho; J Benvenuto; T L Loo; E J Freireich
Journal:  Cancer       Date:  1980-03-15       Impact factor: 6.860

7.  Infusional 5-fluorouracil and X-ray therapy for non-resectable esophageal cancer.

Authors:  J E Byfield; R Barone; J Mendelsohn; S Frankel; L Quinol; T Sharp; S Seagren
Journal:  Cancer       Date:  1980-02-15       Impact factor: 6.860

Review 8.  Oesophageal squamous cell carcinoma: I. A critical review of surgery.

Authors:  R Earlam; J R Cunha-Melo
Journal:  Br J Surg       Date:  1980-06       Impact factor: 6.939

9.  Cisplatin and 5-fluorouracil in the primary management of squamous esophageal cancer.

Authors:  M S Kies; S T Rosen; T K Tsang; R Shetty; P A Schneider; C B Wallemark; T W Shields
Journal:  Cancer       Date:  1987-11-01       Impact factor: 6.860

10.  Cancer of the anal canal. Model for preoperative adjuvant combined modality therapy.

Authors:  L Leichman; N Nigro; V K Vaitkevicius; B Considine; T Buroker; G Bradley; H G Seydel; S Olchowski; G Cummings; C Leichman
Journal:  Am J Med       Date:  1985-02       Impact factor: 4.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.